Drugs / aP booster
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02382913 | Apr → Jun 2015 | pertussis | Novartis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aP booster | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02382913 ↗ |
| Known as | Acellular pertussis (aP) vaccine | “Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.” NCT02382913 ↗ |
| Modality | Vaccine | “Acellular pertussis vaccine” NCT02382913 ↗ |
| Route | Intramuscular | “Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly” NCT02382913 ↗ |